Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | MK-7684A |
Indication/Tumor Type | head and neck squamous cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | head and neck squamous cell carcinoma | predicted - sensitive | MK-7684A | Phase II | Actionable | In a Phase II trial (KEYVIBE-005), MK-7684A treatment resulted in an objective response rate (ORR) of 29% (12/42), a median duration of response of 12.7 months, a median progression survival of 4.1 months, and a median overall survival of 15.5 months in patients with CD274 (PD-L1)-positive (CPS>/=1) head and neck squamous cell carcinoma, with an ORR of 21% (5/24) in patients with CPS=1-19 and an ORR of 41% with CPS>/=20 (Ann Oncol (2024) 35 (Suppl_2): S617-S618; NCT05007106). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
855P Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study | Full reference... |